Welcome, this website is intended for international healthcare professionals with an interest in the treatment of Advanced Prostate Cancer. By clicking the link below you are declaring and confirming that you are a healthcare professional

You are here

Practical management of advanced mCRPC

Nicolas Mottet

14 Practical management of advanced mCRPC - Nicolas Mottet

Professor Nicolas Mottet, Université Jean Monnet, St. Etienne, presents the case of a 62 years old patient with moderately differentiated adenocarcinoma of the prostate (Gleason 7) treated by radical prostatectomy. Two years he relapsed and goserelin and bicalutamide was offered. Following progression he was treated with docetaxel and prednisolone (6 cycles). After a short response PSA level raised to 66 ng/ml and back pain and bone metastases were present. The question is how to treat this patient with progressive mCRPC: docetaxel rechallenge, cabazitaxel, abiraterone plus prednisone, enzalutamide or radium-223?